MX2023009447A - Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos. - Google Patents

Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos.

Info

Publication number
MX2023009447A
MX2023009447A MX2023009447A MX2023009447A MX2023009447A MX 2023009447 A MX2023009447 A MX 2023009447A MX 2023009447 A MX2023009447 A MX 2023009447A MX 2023009447 A MX2023009447 A MX 2023009447A MX 2023009447 A MX2023009447 A MX 2023009447A
Authority
MX
Mexico
Prior art keywords
metapneumovirus
antigenic
antibodies
proteins
bind
Prior art date
Application number
MX2023009447A
Other languages
English (en)
Spanish (es)
Inventor
Aimin Tang
Zhifeng Chen
Lan Zhang
Xiao Xiao
Arthur Fridman
Kara S Cox
Jennifer Dawn Galli
Hua - Poo SU
Kalpit Vora
Zhiyun Wen
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2023009447A publication Critical patent/MX2023009447A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023009447A 2021-02-12 2022-02-08 Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos. MX2023009447A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148920P 2021-02-12 2021-02-12
US202163276172P 2021-11-05 2021-11-05
PCT/US2022/015565 WO2022173714A2 (en) 2021-02-12 2022-02-08 Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof

Publications (1)

Publication Number Publication Date
MX2023009447A true MX2023009447A (es) 2023-10-06

Family

ID=82838690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009447A MX2023009447A (es) 2021-02-12 2022-02-08 Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos.

Country Status (9)

Country Link
US (1) US20240327502A1 (enExample)
EP (1) EP4291232A4 (enExample)
JP (1) JP2024512215A (enExample)
KR (1) KR20230146047A (enExample)
AU (1) AU2022220616A1 (enExample)
BR (1) BR112023016241A2 (enExample)
CA (1) CA3208018A1 (enExample)
MX (1) MX2023009447A (enExample)
WO (1) WO2022173714A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025038512A1 (en) * 2023-08-17 2025-02-20 Merck Sharp & Dohme Llc Methods for detecting pcr chimeras
WO2025097674A1 (zh) * 2023-11-08 2025-05-15 安炎达医药技术(广州)有限公司 一种新型pace4抑制剂及其在抗骨关节炎中的应用
CN119143871B (zh) * 2024-11-20 2025-02-07 首都儿科研究所 用于人偏肺病毒检测的单克隆抗体、检测试剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
US7438907B2 (en) * 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
JP2010505876A (ja) * 2006-10-04 2010-02-25 ザ スクリプス リサーチ インスティテュート ヒトメタニューモウイルスを中和するヒト抗体
JP5642972B2 (ja) * 2007-02-21 2014-12-17 ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
EP2445527A2 (en) * 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CA3138550A1 (en) * 2019-04-30 2020-11-05 Target Discovery Merger Sub II, LLC Cancer associated antibody compositions and methods of use

Also Published As

Publication number Publication date
WO2022173714A3 (en) 2022-11-10
BR112023016241A2 (pt) 2023-11-14
AU2022220616A1 (en) 2023-08-31
WO2022173714A2 (en) 2022-08-18
KR20230146047A (ko) 2023-10-18
EP4291232A2 (en) 2023-12-20
EP4291232A4 (en) 2025-04-02
US20240327502A1 (en) 2024-10-03
CA3208018A1 (en) 2022-08-18
JP2024512215A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
MX2023009447A (es) Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos.
PH12021550974A1 (en) Stablized pre-fusion rsv f proteins
PH12019500862A1 (en) Novel cd47 monoclonal antibodies and uses thereof
PH12019502003A1 (en) Cyclic sulfamide compounds and methods of using same
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
EA200970586A1 (ru) Антитела к цитомегаловирусу человека (hcmv)
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
PH12022553106A1 (en) Sars-cov-2-antibodies and methods of selecting and using the same
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
EA202191736A1 (ru) Комбинированная терапия hbv
MX2023010370A (es) Vacuna del metapneumovirus humano.
MX2021005345A (es) Composiciones y metodos.
EA202191216A1 (ru) НОВЫЕ 6,7-ДИГИДРО-4Н-ПИРАЗОЛО[1,5-a]ПИРАЗИН-ИНДОЛ-2-КАРБОКСАМИДЫ, АКТИВНЫЕ ПРОТИВ ВИРУСА ГЕПАТИТА B (HBV)
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
EA201992626A1 (ru) Способы и композиции для лечения аллергических заболеваний глаз
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
MX2024005962A (es) Composiciones de proteínas de fusión inmunogénicas y métodos de uso de estas
DE60134993D1 (de) Methoden der zubereitung von immunglobulin und dessen verwendungen
JOP20240233A1 (ar) بروتينات cd24 الطافرة واستخداماتها للوقاية من السرطان وعلاجه
WO2021019235A3 (en) Hantavirus antigenic composition
ZA202309368B (en) Lentiviral vector, lentiviral particle for treating hepatitis b and its preparation method and application thereof
WO2020053742A3 (en) Anti-hla-hbv peptide antibodies
PH12021550987A1 (en) Anti-rabies monoclonal antibodies and cocktail thereof
MX2022008036A (es) Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv.